Less than one in 10 patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the global health agency as it publishes its initial advice on the therapies.
Given in excess of 1,000,000,000 people worldwide currently obese, it is advocating for increased and just access to these injectable treatments.
Based on forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"Our new guidelines acknowledges that excess weight is a lifelong illness that can be managed with thorough and lifelong support," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant barriers to universal availability to the jabs that can help people shift significant body mass, notes the body.
GLP-1 Therapy Supply Crisis
Even in the present most optimistic scenario, the supply of GLP-1 therapies might only reach approximately 100 million people – under 10% of those who need them, per the WHO.
The recommendation encourages governments and firms to expand access, by approaches like patent sharing.
A patent on the active ingredient – the core component of a leading brand – is due to expire in several countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a biological compound to delay gastric emptying, suppress the appetite and increase satiety so individuals consume fewer calories.
Patients usually see weight reduction after several weeks of commencing the weekly injections.
Research suggests patients may regain a significant portion a year later of stopping the treatment, when their usual food cravings return.
To be overweight or obese increases your likelihood for experiencing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight concerns individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
